The platform is the asset
A cluster of recent deals shows where capital is moving in computational drug discovery. Lilly partnered with METiS in an arrangement reported at up to about $1.1 billion. Astellas committed more than $400 million to work with AI Proteins. Bristol Myers Squibb agreed to pay about $237 million up front in a collaboration with Pathos valued at up to roughly $3 billion, with a three-year exclusive scope, and Pathos separately licensed data from Tempus for about $55 million.
The common feature is that the buyers are not only paying for a molecule. They are paying for the engine that produces molecules. When a platform shows it can generate candidates a partner wants, the platform itself becomes the asset being valued, and the deals are structured around access to it over time rather than a single program.
For a platform company, that creates a real choice. One path is to build the platform out alone, funding each step with more capital. The other is to let a partner carry it, converting the platform's promise into committed cash and shared development while the inventors stay on the science. Which path serves the company depends on the asset and the owner's goals, and that is the conversation we have before any outreach begins.
Nothing here is investment advice, and this note is not an endorsement of any transaction described. Figures are as publicly reported.
Filling a pipeline gap?
Talk to us →Have a program worth de-risking?
See how we work with inventors →